A Clinical Study of NAD in the Treatment of Immune Thrombocytopenia
Status:
RECRUITING
Trial end date:
2026-03-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety and efficacy of nicotinamide adenine dinucleotide in the treatment of immune thrombocytopenia in patients who have not responded adequately or relapsed after first-line treatment and at least one second-line therapy including Anti-CD20 Antibody and/or TPO-RA.
Phase:
PHASE1
Details
Lead Sponsor:
Institute of Hematology & Blood Diseases Hospital, China